The Liver Diseases Therapeutics Market, estimated at USD 20.5 Bn in 2025, is expected to exhibit a CAGR of 9.8% and reach USD 39.44 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The initiatives by government organizations to conduct awareness programs regarding liver health can drive the growth of the global liver diseases therapeutics market over the forecast period. For instance, on May 24, 2025, American Liver Foundation announced a nationwide public awareness program campaign ‘Think Liver Think Life’ to test at-risk children and adults in all 50 states over the next five years. The campaign includes liver panels, viral hepatitis antibody screening, and assessments to help identify nonalcoholic steatohepatitis and liver cancer. It also includes a public awareness campaign, patient and provider education, a resource and information center
Global Liver Diseases Therapeutics Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global liver diseases therapeutics market. This is because of the reduced demand for liver disease therapeutics during the COVID period due to reduced patient visits during the lockdown period. For instance, according to an article published by Lancet Gastroenterology and Hepatology on June 29, 2025, a study was performed between February 19, 2025, to April 30, 2025, in 124 hospital administrations for liver-related disorders at hepatology and transplant centers, in Iran. The results showed a significant decrease in the number of hospital admissions for liver-related disorders during the COVID-19 pandemic compared with the control period in 2025 at a large hepatobiliary referral center. This decrease is probably due to the implementation of physical distancing regulations, the psychosocial effects of the COVID-19 outbreak, and recommendations to postpone clinical visits for patients with chronic liver diseases.
Global Liver Diseases Therapeutics Market: Key Developments
Strategies like mergers and acquisitions can increase the reach of the products and customer base of acquiring company, and the product can reach more regions. This is expected to boost market growth during the forecast period.
For instance, on May 15, 2025, Aligos Therapeutics, U.S. based biotherapeutic company, and Xiamen Amoytop Biotech Co. Ltd., a China-based biotechnology company, entered into a research collaboration and development deal to use the oligonucleotide platform of aligos for liver disease treatment. Both companies will work on the research and development of oligonucleotide compounds to treat liver diseases. Amoytop will gain the exclusive right to develop and commercialize the resulting products in the Greater China territory. Aligos Therapeutics will retain rights for the rest of the world. Aligos will receive an upfront payment and research collaboration funding, along with development and sales milestone payments of US$ 109 million for licensed products and tiered royalties on net sales.